The experimental coronavirus treatment remdesivir has failed in its first randomized clinical trial, inadvertently released results showed on Thursday, dampening expectations for the closely watched drug.
A draft summary went online briefly on the WHO Web site and was first reported by the Financial Times and health news Web site Stat, which posted a screenshot.
However, Gilead Sciences, the company behind the medicine, disputed how the now-deleted post had characterized the findings, saying that the data showed a “potential benefit.”
Photo: AFP
The Chinese trial involved 237 patients, with 158 on the drug and 79 in a control group, the summary said, adding that remdesivir was stopped early in 18 patients because of side effects.
The authors said that remdesivir was “not associated with a difference in time to clinical improvement” compared with the control.
After a month, 13.9 percent of the patients on remdesivir had died, compared with 12.8 percent of those in the control group. The difference is not statistically significant.
The WHO told the Financial Times that the draft is undergoing peer review and was published early in error.
“We believe the post included inappropriate characterizations of the study,” a Gilead spokesman told reporters, adding that it was terminated early due to low enrollment and was therefore not statistically meaningful.
“As such, the study results are inconclusive, though trends in the data suggest a potential benefit for remdesivir, particularly among patients treated early in disease,” the spokesman said.
The study does not represent the final word on the matter, and there are several large-scale trials in advanced stages that should soon provide a clearer picture.
Remdesivir, which is administered intravenously, was among the first drugs suggested as a treatment for the novel coronavirus and as such has great hopes riding on it.
Last week, Stat reported that it had shown significant efficacy at a Chicago hospital where patients who are part of one of the major trials are being treated.
The US National Institutes of Health also reported it that had proven effective in a small experiment on monkeys.
Remdesivir, which previously failed in trials against Ebola, belongs to a class of drugs that act on the virus directly — as opposed to controlling the abnormal and often lethal autoimmune response it causes. It mimics one of the four building blocks of RNA and DNA, and gets absorbed into the virus’ genome, which in turn stops the pathogen from replicating.
Anti-malarial drugs hydroxychloroquine and chloroquine have also been widely used on COVID-19 on a so-called “compassionate basis” pending results from large trials, with early studies decidedly mixed.
Other therapies that are being studied include collecting antibodies from COVID-19 survivors and injecting them in patients, or harvesting antibodies from genetically engineered mice that were deliberately infected.
Separately in France, new research shows that nicotine could protect people from contracting COVID-19.
The findings came after researchers at a top Paris hospital examined 343 COVID-19 patients, as well as 139 people with the illness who had milder symptoms.
They found that a low number of them smoked, compared with smoking rates of about 35 percent in France’s general population.
“Among these patients, only 5 percent were smokers,” said Zahir Amoura, the study’s coauthor and a professor of internal medicine.
The research echoed similar findings published in the New England Journal of Medicine last month suggesting that 12.6 percent of 1,000 people infected in China were smokers.
That was a much lower figure than the number of regular smokers in China’s general population, about 26 percent, WHO data showed.
The theory is that nicotine could adhere to cell receptors, therefore blocking the novel coronavirus from entering cells and spreading in the body, said neurobiologist Jean-Pierre Changeux from France’s Pasteur Institute, who also coauthored the study.
The researchers are awaiting approval from health authorities to carry out further clinical trials.
The researchers are looking into whether nicotine could help to prevent “cytokine storms,” a rapid overreaction of the immune system that scientists think could play a key role in fatal COVID-19 cases.
However, with further research needed, experts are not encouraging people to pick up smoking or use nicotine patches as a protective measure against the virus.
“We must not forget the harmful effects of nicotine,” French Director-General for Health Jerome Salomon said.
“Those who do not smoke should absolutely not use nicotine substitutes,” which cause side effects and addiction, he said.
Former Nicaraguan president Violeta Chamorro, who brought peace to Nicaragua after years of war and was the first woman elected president in the Americas, died on Saturday at the age of 95, her family said. Chamorro, who ruled the poor Central American country from 1990 to 1997, “died in peace, surrounded by the affection and love of her children,” said a statement issued by her four children. As president, Chamorro ended a civil war that had raged for much of the 1980s as US-backed rebels known as the “Contras” fought the leftist Sandinista government. That conflict made Nicaragua one of
COMPETITION: The US and Russia make up about 90 percent of the world stockpile and are adding new versions, while China’s nuclear force is steadily rising, SIPRI said Most of the world’s nuclear-armed states continued to modernize their arsenals last year, setting the stage for a new nuclear arms race, the Stockholm International Peace Research Institute (SIPRI) said yesterday. Nuclear powers including the US and Russia — which account for about 90 percent of the world’s stockpile — had spent time last year “upgrading existing weapons and adding newer versions,” researchers said. Since the end of the Cold War, old warheads have generally been dismantled quicker than new ones have been deployed, resulting in a decrease in the overall number of warheads. However, SIPRI said that the trend was likely
BOMBARDMENT: Moscow sent more than 440 drones and 32 missiles, Volodymyr Zelenskiy said, in ‘one of the most terrifying strikes’ on the capital in recent months A nighttime Russian missile and drone bombardment of Ukraine killed at least 15 people and injured 116 while they slept in their homes, local officials said yesterday, with the main barrage centering on the capital, Kyiv. Kyiv City Military Administration head Tymur Tkachenko said 14 people were killed and 99 were injured as explosions echoed across the city for hours during the night. The bombardment demolished a nine-story residential building, destroying dozens of apartments. Emergency workers were at the scene to rescue people from under the rubble. Russia flung more than 440 drones and 32 missiles at Ukraine, Ukrainian President Volodymyr Zelenskiy
Indonesia’s Mount Lewotobi Laki-Laki yesterday erupted again with giant ash and smoke plumes after forcing evacuations of villages and flight cancelations, including to and from the resort island of Bali. Several eruptions sent ash up to 5km into the sky on Tuesday evening to yesterday afternoon. An eruption on Tuesday afternoon sent thick, gray clouds 10km into the sky that expanded into a mushroom-shaped ash cloud visible as much as 150km kilometers away. The eruption alert was raised on Tuesday to the highest level and the danger zone where people are recommended to leave was expanded to 8km from the crater. Officers also
RSS